Below are the comments filed by Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) regarding a prospective grant of an exclusive license of NIH-owned patents to the California-based company Midissia Therapeutics. The prospective exclusive license is… Continue Reading
UPDATE: On Wednesday, 15 August 2018, WHO Director-General, Dr Tedros Adhanom Ghebreyesus provided a response to the open letter on the Roadmap on Access to Medicines and Vaccines 2019-2023. The Director-General’s response can be found here: WHO DG letter to… Continue Reading
The following is a question for the record from Senator Sherrod Brown, and a response from Alex Azar, in connection with Azar’s confirmation hearing. Questions for the Record January 9, 2018 Hearing to Consider the Nomination of Alex Azar to… Continue Reading
This is the July 26, 2018 draft of the UN declaration on NCDs. NCD-Draft-co-facilitators-text-26July2018 [The earlier July 16, 2018 draft is available here: NCD-POL-DECLARATION-16JUL2018] To nobody’s surprise, the July 26, 2018 version is very weak. In the July 26, 2018… Continue Reading
On 26 September 2018, the United Nations’ General Assembly will convene the first high-level meeting on tuberculosis; the theme of the meeting is “United to end tuberculosis: an urgent global response to a global epidemic”. In preparation for the United… Continue Reading
The new House democrats medicare negotiations bill represents a turning point, with broad support for using robust compulsory licensing authority to protect access if negotiations on prices break down. The press conference announcing the bill featured several Democratic members of… Continue Reading
On July 18, 2018, the U.S. House Energy and Commerce committee gave its approval to HR 6378, the Pandemic and All-Hazards Preparedness Act, known as PAHPA. During the mark up, Reps. John Shimkus (R-IL) and Tony Cárdenas (D-CA) proposed attaching… Continue Reading
The following are comments by the KEI on the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, in response to notice in the Federal Register, 83 FR 22692. Overall, the Blueprint is very weak, and won’t do much… Continue Reading
Attached are comments from 8 health and fair groups regarding a prospective grant of an exclusive license to NIH owned patent, for the development of an Anti-Mesothelin Chimeric Antigen Receptor (CAR) for the treatment of human Cancer, to Atara Biotherapeutics… Continue Reading
At around 16h35 on Thursday, 12 July 2018, the WIPO Secretariat distributed the final text of the future work program of the Standing Committee on the Law of Patents (SCP). The final text can be found here: http://www.wipo.int/edocs/mdocs/scp/en/scp_28/scp_28_11.pdf The new… Continue Reading